IRIX IRIDEX CORP

Nasdaq Electromedical & Electrotherapeutic Apparatus DE CIK: 0001006045
AI RATING
SELL
78% Confidence

Investment Thesis

IRIX is unprofitable with negative operating cash flow despite 8.2% revenue growth, indicating operational inefficiency and cash burn that will strain the company's limited equity base. While net losses improved 50.2% YoY, the company must achieve operating profitability within 12-18 months to avoid liquidity pressure given only $6M in cash reserves supporting a $4.9M equity base.

Strengths

  • + Revenue growth of 8.2% YoY demonstrates market demand in electromedical device sector
  • + Net loss improved 50.2% YoY, indicating operational progress and path toward profitability
  • + Healthy gross margin of 36.5% suggests product pricing power and reasonable cost of goods
  • + Strong liquidity with current ratio of 1.91x and quick ratio of 1.32x
  • + Low leverage at 0.20x debt-to-equity limits financial distress risk from debt servicing

Risks

  • ! Negative operating cash flow of -$2.1M despite positive revenue indicates business model is not self-sustaining and cash runway is limited
  • ! Operating margin of -4.9% and net margin of -8.4% show company is unprofitable at scale; SG&A expenses appear excessive relative to revenue
  • ! Stockholders equity of only $4.9M against $24.2M liabilities leaves minimal buffer for operational losses; company is equity-constrained
  • ! Negative free cash flow of -$2.3M means company cannot fund growth or debt repayment from operations and is depleting cash reserves
  • ! Minimal insider activity (3 Form 4 filings in 90 days) suggests low confidence or activism from leadership regarding turnaround trajectory

Key Metrics to Watch

Financial Metrics

Revenue
52.7M
Net Income
-4.4M
EPS (Diluted)
$-0.26
Free Cash Flow
-2.3M
Total Assets
29.2M
Cash
6.0M

Profitability Ratios

Gross Margin 36.5%
Operating Margin -4.9%
Net Margin -8.4%
ROE -90.1%
ROA -15.2%
FCF Margin -4.3%

Balance Sheet & Liquidity

Current Ratio
1.91x
Quick Ratio
1.32x
Debt/Equity
0.20x
Debt/Assets
83.1%
Interest Coverage
-44.33x
Long-term Debt
1.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-14T08:38:37.020321 | Data as of: 2026-01-03 | Powered by Claude AI